Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. grew its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 1.4% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 290,226 shares of the biopharmaceutical company's stock after acquiring an additional 3,883 shares during the period. Gilead Sciences comprises approximately 0.5% of Oppenheimer & Co. Inc.'s investment portfolio, making the stock its 29th biggest position. Oppenheimer & Co. Inc.'s holdings in Gilead Sciences were worth $32,520,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the company. Annis Gardner Whiting Capital Advisors LLC raised its position in Gilead Sciences by 158.8% during the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock worth $33,000 after acquiring an additional 216 shares during the period. Whipplewood Advisors LLC acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at about $35,000. Synergy Investment Management LLC purchased a new stake in shares of Gilead Sciences during the fourth quarter worth about $40,000. Lee Danner & Bass Inc. acquired a new position in shares of Gilead Sciences during the 4th quarter worth about $41,000. Finally, Investment Research & Advisory Group Inc. lifted its stake in Gilead Sciences by 33.3% in the 1st quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company's stock valued at $45,000 after buying an additional 100 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Trading Down 2.1%

GILD traded down $2.31 on Monday, hitting $106.19. The company had a trading volume of 8,170,901 shares, compared to its average volume of 7,663,622. The company's fifty day moving average price is $106.16 and its 200 day moving average price is $102.98. Gilead Sciences, Inc. has a 1 year low of $66.01 and a 1 year high of $119.96. The company has a current ratio of 1.37, a quick ratio of 1.23 and a debt-to-equity ratio of 1.16. The firm has a market cap of $132.09 billion, a P/E ratio of 22.36, a PEG ratio of 0.70 and a beta of 0.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The business had revenue of $6.67 billion during the quarter, compared to analysts' expectations of $6.77 billion. During the same period last year, the business earned ($1.32) earnings per share. The business's revenue for the quarter was down .3% on a year-over-year basis. As a group, equities analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be paid a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.98%. The ex-dividend date is Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is 66.53%.

Insiders Place Their Bets

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction on Monday, June 16th. The stock was sold at an average price of $110.17, for a total value of $275,425.00. Following the sale, the chief financial officer now owns 165,110 shares in the company, valued at approximately $18,190,168.70. The trade was a 1.49% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction dated Friday, May 30th. The shares were sold at an average price of $110.42, for a total value of $1,104,200.00. Following the transaction, the chief executive officer now owns 620,268 shares of the company's stock, valued at $68,489,992.56. This trade represents a 1.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 48,500 shares of company stock worth $5,236,245 over the last ninety days. Corporate insiders own 0.27% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. Morgan Stanley lifted their price target on Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research note on Friday, April 25th. Oppenheimer dropped their price target on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research report on Friday, April 25th. Cantor Fitzgerald started coverage on Gilead Sciences in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price objective for the company. Finally, Wells Fargo & Company lifted their target price on shares of Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. Nine research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $110.55.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.